3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Status
Recruiting
2
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
4
Sponsor
Cancer Type
Thoracic
16
Tumor-Agnostic
4
Lymphoid
3
CNS
3
Other hematologic neoplasm
2
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Conditions
Neoplasms
2
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Interventions
pembrolizumab
56
Specimen Handling
28
Biopsy
27
Magnetic Resonance Spectroscopy
26
Paclitaxel
22
Blood Specimen Collection
21
Nivolumab
20
atezolizumab
18
Standard of Care
18
Carboplatin
18
Surveys and Questionnaires
17
Bevacizumab
17
Oxaliplatin
13
Fluorouracil
13
Cisplatin
13
Radiotherapy
12
Radiosurgery
12
Cyclophosphamide
12
Pemetrexed
11
Leucovorin
11
Irinotecan
10
Gemcitabine
10
Docetaxel
10
Capecitabine
10
trastuzumab deruxtecan
8
olaparib
8
Taxes
8
Ipilimumab
8
durvalumab
7
Trastuzumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
alectinib
×
Tumor-Agnostic
×
1 year
×
Clear all
NCT03768063
2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3
Active not recruiting
1,000 enrolled
NCT04116541
2026-04-24
MegaMOST
Centre Leon Berard
Phase 2
Recruiting
455 enrolled
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts
NCT04341181
2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2
Recruiting
300 enrolled